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PROBLEM IDENTIFICATION 
More than 60 million persons in the United States report symptoms of gastroesophageal reflux disease 
(GERD) at least weekly, and a typical full-time family physician can expect to diagnose and treat 40 to 60 
patients with this condition each month (1)
A recent 2020 study that surveyed 71,812 individuals in the US, found that 2 out of 5 participants have had 
GERD symptoms in the past and 1 out of 3 had symptoms in the past week (2)
Proton pump inhibitors (PPIs) are considered the mainstay of medical therapy for GERD. 
Currently, the American Academy of Family Physician recommends that PPIs be used when a patient is 
exhibiting signs and symptoms of GERD, which include heartburn & regurgitation. The recommendation 
includes starting patients with suspected GERD on the lowest effective dose PPI and shortest duration of 
therapy, with a typical regimen lasting 2-12 weeks. (1, 7)
Yet even with these guidelines' patients are often kept on PPIs for months or years without adequate 
diagnostic reason. 
PROBLEM IDENTIFICATION 
While PPIs are highly effective at reducing stomach acid, they are not without risks. Short term uses of PPIs are generally 
well tolerated and involve little risk; however, chronic use of PPIs is associated with significant side effects including (5): 
• Diarrhea
• Impaired B12 absorption
• Hypomagnesemia
• Clostridium difficile infection
• Hip fractures
• Pneumonia. 
There are currently no guidelines for PPI tapering (6)  
PPIs have also become widely accessible to patients as 
many of them are currently available over the counter 
and require no prescription, which has also allowed 
for patients to continue PPI therapy without direct 
guidance from a healthcare provider
The aim of this project is to determine the barriers 
that prevent PPI deprescribing in cases of GERD
PUBLIC HEALTH COST
While PPIs are highly effective at managing GERD, they can be quite costly to the patient and can 
pose a large economic burden
It has been estimated that prescribed medications for GERD, primarily PPIs, account for over 50% of 
prescriptions for all digestive diseases, resulting in around $10 billion in annual direct health care 
costs (3)
A 2010  study found that the PPI, esomeprazole, accrued more than $5.2 billion in sales in the US (3) 
A 2014 study identified that $6.69 billion was paid by patients taking high-cost PPIs (4). 
COMMUNITY HEALTH PERSPECTIVE 
What do you think are the major barriers for PPI deprescribing? 
There is no question that PPI deprescribing is very important. Unfortunately, patients feel that there is never a good time to go off a potentially 
dangerous medication and having a good conversation with the patients on risks and benefits, tapering the medication takes a long time. Rarely 
patients follow up for GERD alone and they have a full agenda for other reasons to come for a follow up. I have made a point to deescalate 
therapy and these efforts were blocked recently by the poor availability of H2 blockers as well as the pulling off the market of Ranitidine for a 
few months. Recently there has been a shortage of Famotidine. The rebound from PPIs can be significant, a despite using H2 blockers there is a 
period of discomfort that the patients feel and most of them call back that they want back on medication. –Dr. Alex Mosteanu, MD
Major barriers for PPI deprescribing include provider and patient awareness of the current evidence in therapy duration, the side effects of 
chronic PPI use, and a lack of continuity in prescription refills/ management. –Dr. Nick Florio, MD
How do you think PPI management can be improved? 
PPI management can be improved by educating both patients and providers in current evidence-based guidelines on duration of therapy, side 
effects of chronic PPI use, deprescribing algorithms and increasing patient continuity for office visits and refill requests. –Dr. Nick Florio, MD
Better patient education- pamphlets; better availability of H2 blockers; many times, GI is starting patients on PPIs and the plan for short course is 
not clearly stated. Some patients have indication for longer course (Barrett’s) but there is no clear plan on when these meds need to be started 
and tapered. Patients will do much better if the plan of therapy is discussed from the beginning with the expectation of what will happen after 
2-3 months of therapy (de-escalating discussion). –Dr. Alex Mosteanu, MD 
In order to gain community perspective, I reached out to two medical providers at the Ridgefield Primary Care 
office about PPI deprescribing in the primary setting 
Using the information gathered from interviews with physicians in the Ridgefield office,  a survey was created using 
SurveyMonkey and distributed to medical providers at Ridgefield Primary Care and Newtown Primary Care to 
determine perspectives on PPI management for GERD and to understand what barriers currently prevent PPI deprescribing.
INTERVENTION
INTERVENTION
A pamphlet for  patients was created and 
given to providers along with the survey.
The last question of the survey asked 
providers if they thought that the 
pamphlet would help educate patients on 
long-term side effects of PPIs
RESULTS
All providers (100%) agree that:
• PPI deprescribing for GERD is important
• Telehealth visits may help with deprescribing PPI’s for GERD
• The patient pamphlet that I created would help with patient education on the topic
These results suggest that there is awareness amongst providers regarding PPI management. Given that 
telehealth has become common practice in the age of COVID, it may be useful to help manage patients 
GERD and start PPI tapering if possible. 
5/10 of the providers surveyed 
often have patients initiating a 
PPI for GERD without provider 
recommendation 
Some PPIs are available OTC, which make them hard to manage. 
These results indicate that patient 
education may be important for PPI use 
management. 
10 total survey responses were collected 
RESULTS
The question regarding barriers only received 8 responses, meaning 
2 providers did not respond. Unclear as to why but could be due to 
confusion regarding the question.  
From the 8 responses collected, 2 main barriers were 
established:
• Multiple providers involved in PPI management (6/8)
• Patient reluctance to decrease PPI (5/8)
These results suggests that efforts to prevent PPI prescriptions from 
being filled by non-initiating providers could assist in management of 
PPI. Patient education regarding the risks associated with PPI chronic 
use may also make patients more willing to consider tapering. 
~37.5%  of providers surveyed also found constraints of 
office visit time and OTC availability of PPIs to be 
important barriers. 
EFFECTIVENESS AND LIMITATIONS 
The effectiveness of this intervention will be determined in future months by the number of patients that talk to their 
provider about their PPI use.  Whether it is the provider or the patient that decides to start a conversation about chronic 
PPI use, the mere fact that the conversation is occurring can be considered a win. 
Future assessment of effectiveness
• A follow up survey in the next few months to see if providers have engaged in more patient discussion regarding PPIs
• Conduct a survey involving pharmacists to determine their perspective on over-the counter PPI use
• Determine if the presence of the brochure in the office increased patient interest in PPI tapering
Limitations of the project
• There still are not concrete guidelines for how patients should be tapered off their PPI
• PPIs are still available over the counter, which makes it an ongoing challenge for providers to monitor patient PPI use
• Patients often feel very comfortable on PPI therapy and may not change even with education via a pamphlet or 
provider 
• Only 8/10 providers answered the survey question regarding barriers to PPI tapering
FUTURE PROJECTS
• Distribute pamphlets to the Ridgefield Primary Care office as well as other offices in the 
Danbury area 
• Consider pamphlet distribution at nearby pharmacies 
• Consider conducting an educational seminar on PPI management with gastroenterology. 
• Compile data on the effectiveness of the pamphlet in initiating conversation regarding 
PPI use
• Follow up with patients that have tapered off PPI and collect data regarding their 
perspective of the tapering/ deprescribing process 
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